Neumora Therapeutics, Inc. NMRA 深 沪
已收盘 02-06 16:00:00 美东时间
2.12
+0.160
+8.16%
华盛通- 最 高2.16
- 今 开2.02
- 成交量 111.53万股
- 最 低 1.98
- 昨 收 1.96
- 总市值 3.60亿
- 52周最高 3.25
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 0.611
- 委 比 -45.70%
- 总股本 1.70亿
- 历史最高 21.00
- 量 比 1.82
- 振 幅 9.18%
- 历史最低 0.611
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Leerink Partners Initiates Coverage On Neumora Therapeutics with Outperform Rating, Announces Price Target of $8
Leerink Partners analyst Marc Goodman initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Outperform rating and announces Price Target of $8.
01-12 20:44
Neumora Therapeutics Says KOASTAL-2 And -3 On Track For Consolidated Topline Readout In Q2 2026; Plans To Conduct NMRA-215 Clinical Program In 2026 Following Preclinical Data From Diet Induced Obesity Model
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creationKOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026Plans to conduct NMRA-215
01-12 20:22
Neumora Therapeutics Announces Results From Phase 1b Signal-Seeking Study Of NMRA-511 In People With Alzheimer's Disease Agitation
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population
01-12 20:21
美股牛股 | 脑机接口概念持续强势！脑再生科技大涨超60%；Revolution涨超28.6%
脑机接口概念持续强势！脑再生科技大涨超60%，近四日涨幅超150%；“收购传闻”引股价过山车，Revolution隔夜涨超28.6%，盘后跌超6%>>
01-08 15:53
Neumora's Alzheimer's Agitation Drug Shows Early Promise
NMRA-511 showed promising results in Phase 1b study for Alzheimer's disease agitation with favorable tolerability and safety profile.
01-06 00:11
Neumora Therapeutics Reports Results From NMRA-511 Phase 1b Signal-Seeking Study In People With Alzheimer's Disease Agitation
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population
01-05 19:31
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of key 2026 readouts.
2025-12-02 02:45
RBC Capital Upgrades Neumora Therapeutics to Outperform, Raises Price Target to $7
RBC Capital analyst Brian Abrahams upgrades Neumora Therapeutics (NASDAQ:NMRA) from Sector Perform to Outperform and raises the price target from $4 to $7.
2025-12-01 19:33
